Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2001-06-06
2004-03-09
Mertz, Prema (Department: 1646)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S071100, C435S071200, C435S325000, C435S252300, C435S254110, C435S320100, C435S471000, C530S350000
Reexamination Certificate
active
06703495
ABSTRACT:
1. INTRODUCTION
The present invention relates to the discovery, identification, and characterization of novel human polynucleotides encoding proteins that share sequence similarity with mammalian transporter proteins. The invention encompasses the described polynucleotides, host cell expression systems, the encoded proteins, fusion proteins, polypeptides and peptides, antibodies to the encoded proteins and peptides, and genetically engineered animals that either lack or over express the disclosed polynucleotide sequences, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed polynucleotide sequences that can be used for diagnosis, drug screening, clinical trial monitoring, the treatment of diseases and disorders, and cosmetic or nutriceutical applications.
2. BACKGROUND OF THE INVENTION
Transporter proteins are integral membrane proteins that mediate or facilitate the passage of materials across the lipid bilayer. Given that the transport of materials across the membrane can play an important physiological role, transporter proteins are good drug targets. Additionally, one of the mechanisms of drug resistance involves diseased cells using cellular transporter systems to export chemotherapeutic agents from the cell. Such mechanisms are particularly relevant to cells manifesting resistance to a multiplicity of drugs.
3. SUMMARY OF THE INVENTION
The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with mammalian ion transporters, sulfate transporters, and particularly the sulfate transporter that has been associated with diastrophic dysplasia.
The novel human nucleic acid sequences described herein, encode alternative proteins/open reading frames (ORFs) of 679, 621, 663, 605, 656, and 598 amino acids in length (see respectively SEQ ID NOS: 2, 4, 6, 8, 10, and 12. The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof, that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP polynucleotides (e.g., expression constructs that place the described polynucleotide under the control of a strong promoter system), and transgenic animals that express a NHP transgene, or “knock-outs” (which can be conditional) that do not express a functional NHP. Knock-out mice can be produced in several ways, one of which involves the use of mouse embryonic stem cells (“ES cells”) lines that contain gene trap mutations in a murine homolog of at least one of the described NHPs. When the unique NHP sequences described in SEQ ID NOS:1-13 are “knocked-out” they provide a method of identifying phenotypic expression of the particular gene as well as a method of assigning function to previously unknown genes. Additionally, the unique NHP sequences described in SEQ ID NOS:1-13 are useful for the identification of coding sequence and the mapping a unique gene to a particular chromosome.
Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.
REFERENCES:
patent: WO 94/20616 (1994-09-01), None
patent: WO 01/70979 (2001-03-01), None
Bork et al, TIG, vol. 12, No. 10, pp. 425-427, Oct. 1996.*
Doerks et al., TIG, vol. 14, No. 6, pp. 248-250, Jun. 1998.*
Brenner et al , TIG, vol. 15, No. 8, pp. 132-133, Apr. 1999.*
Database EMBL Sequence Database Online! EMBL; EST Acc No. AA992584, Jun. 5, 1998, Strausberg R.: “ot97f04.s1 Soares total fetus Nb2HF8 9wHomo sapienscDNA clone”, XP002195361, abstract.
Girard Jean-Philippe et al: “Molecular cloning and functional analysis of SUT-1, a sulfate transporter from human high endothelial venules”, PNAS of USA, National Academy of Science, Washington, US, vol. 96, No. 22, Oct. 26, 19999, paes 12772-12777, XP002147877, ISSN: 0027-8424.
Haestbacka J. et al: “The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping”, Cell, Cell Press, Cambridge, NA, US, vol. 78, No. 6, Sep. 23, 1994, pp. 1073-1087, XP000571593, issn: 0092-8674.
International Search Report.
Scoville John
Walke D. Wade
Lexicon Genetics Incorporated
Mertz Prema
LandOfFree
Polynucleotides encoding human transporter protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding human transporter protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding human transporter protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3245187